Agilent Technologies Inc. (NYSE: A) today announced that it has entered into a licensing agreement with BioDiscovery, Inc., enabling BioDiscovery customers to access Agilent SureFISH probes directly from BioDiscovery’s Nexus software. Researchers using a variety of cytogenetic microarray platforms can now quickly identify aberrations via Nexus and immediately identify/link to available oligonucleotide-based fluorescent in situ […]
UNION CITY, Calif., — Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point of care instruments and consumables for the medical, research, and veterinary markets, and providing reference lab services to the veterinary and research markets, announced today that a settlement had been reached in its lawsuit with Cepheid, Inc. (NasdaqGS: CPHD), over several […]
SUNNYVALE, Calif., — Cepheid (Nasdaq: CPHD) today announced preliminary revenue results for the 2012 Third Quarter, ending September 30, 2012. Based on current projections, Third Quarter revenue is expected to be in the range of $79 to $81 million, lower than targeted due primarily to intermittent interruptions in the supply of Xpert cartridge parts. The […]
Melbourne, Australia; — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce that BREVAGen™ has been cleared for sale into the State of Florida following the grant of a permit to the Company’s Australian-based laboratory by the Clinical Laboratory Unit of the Florida Agency for Healthcare Administration (“AHCA”). This news follows the Company’s […]
Mansfield, MA,– PrimeraDx, Inc., a molecular diagnostics company, announced today that they were awarded a grant by the National Cancer Institute-sponsored Innovative Molecular Analysis Technologies (IMAT) Program to develop an assay to rapidly detect diffuse large B-Cell lymphoma (DLBCL) subgroups. This single-tube gene expression profiling assay will be used for classifying DLBCL subgroups, thereby facilitating […]
Life Technologies Launches Pervenio™ Lung RS, a Risk Stratification Test for Early Stage Lung Cancer
CARLSBAD, Calif., — Life Technologies Corporation (NASDAQ:LIFE) today announced the launch of Pervenio™ Lung RS. First-of-its-kind, the molecular test has been documented to reliably identify early stage lung cancer patients who are at high risk for mortality following surgery. It also fulfills an unmet need for prognostic information to guide preventative treatment and improve disease […]
Cambridge, UK and MA –– Innovative technology design and development firm Cambridge Consultants is working with Singapore-based Clearbridge BioMedics on a groundbreaking device to improve cancer testing and research. The innovative second-generation ClearCellTM System enables tumor cells to be retrieved and detected even faster, and potentially more accurately, from a simple blood sample – paving […]
OMAHA, Neb. — Transgenomic, Inc. (OTCBB: TBIO) announced today that it has closed the previously announced acquisition of Axial Biotech’s ScoliScore™ Adolescent Idiopathic Scoliosis (AIS) Prognostic Test for a total consideration of $4.4 million in cash. The acquisition provides Transgenomic with the ScoliScore™ assay technology and intellectual property, an established revenue and customer base, and […]
BlueGnome, which was founded in 2002 by Cambridge graduate Dr Nick Haan and Graham Snudden, is one of the fastest-growing biotechnology companies in the UK. The company’s products are supplied to hospitals, specialist genetic centres, and IVF clinics in more than 40 countries. This year, the company opened a new North American headquarters near Washington, […]
SAN DIEGO — Illumina, Inc. (NASDAQ:ILMN) today announced that it has acquired Cambridge, U.K.-based BlueGnome Ltd. for an undisclosed sum. BlueGnome, now a wholly owned subsidiary of Illumina, is a leading provider of solutions for the screening of genetic abnormalities associated with developmental delay, cancer, and infertility. “The BlueGnome acquisition supports Illumina’s goal to be […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
